Holen Sie sich die Stockscreener-App
25.93
6.48%
1.555
Handel nachbörslich:
25.93
0.005
+0.02%
Schlusskurs vom Vortag:
$24.37
Offen:
$25
24-Stunden-Volumen:
362.54K
Relative Volume:
1.17
Marktkapitalisierung:
$1.79B
Einnahmen:
$751.00K
Nettoeinkommen (Verlust:
$-74.57M
KGV:
-23.50
EPS:
-1.1031
Netto-Cashflow:
$-55.52M
1W Leistung:
+4.47%
1M Leistung:
+5.70%
6M Leistung:
+83.65%
1J Leistung:
+64.55%
1-Tages-Spanne:
$24.36
$26.41
1-Wochen-Bereich:
$24.27
$28.48
52-Wochen-Spanne:
$12.56
$28.53
Pulse Biosciences Inc Stock (PLSE) Company Profile
Firmenname
Pulse Biosciences Inc
Sektor
Telefon
510-906-4600
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
25.93 | 1.69B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
416.55 | 145.58B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
145.52 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.29 | 32.60B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.33 | 30.96B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
192.74 | 28.25B | 5.54B | 1.52B | 1.74B | 10.37 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | Mizuho | Outperform |
| 2025-07-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-07-27 | Eingeleitet | Stephens | Overweight |
| 2021-03-11 | Eingeleitet | Maxim Group | Buy |
| 2021-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-12 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten
Pulse Bio to redeem remaining common stock warrants - MSN
Pulse Biosciences Shareholders Approve Board and Auditor Slate - TipRanks
Pulse Biosciences (PLSE) investors back all directors and Deloitte as 2026 auditor - Stock Titan
Pulse Biosciences Stock (US73242P1030): Shares in focus after recent conference appearance - AD HOC NEWS
Pulse Biosciences (PLSE) upgraded to buy: What does it mean for the stock? - MSN
Pulse Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
PLSE: Directors and auditor ratified as company advances AFib trial and strengthens leadership - TradingView
Pulse Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Pulse Biosciences (PLSE) to Redeem Outstanding Warrants by June 2026 - GuruFocus
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants - Investing News Network
Pulse Bio to redeem common stock warrants (PLSE:NASDAQ) - Seeking Alpha
Pulse Biosciences Announces Redemption of Remaining 200% Warrants - TipRanks
Pulse Biosciences to redeem remaining warrants after VWAP triggers; exercise window until July 13, 2026 - TradingView
Warrant redemption may add up to $2.1M for Pulse Biosciences (PLSE) - Stock Titan
Pulse Biosciences to redeem outstanding warrants by July 13 - Investing.com UK
Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants - TradingView
Avoiding Lag: Real-Time Signals in (PLSE) Movement - Stock Traders Daily
Did New Analyst Coverage and Insider Buying Just Shift Pulse Biosciences' (PLSE) Investment Narrative? - Yahoo Finance
Does Pulse Biosciences’ (PLSE) Insider Buying Reinforce Canaccord’s Cardiac PFA Thesis or Raise New Questions? - Sahm
Pulse Biosciences board approves affiliate participation in equity sales program - Investing.com
Pulse Biosciences (PLSE) Initiated with Buy Rating and $32 Targe - GuruFocus
Canaccord initiates Pulse Biosciences stock with buy on ablation tech - Investing.com UK
Pulse Biosciences (PLSE) Surges 7.8%: Volume-Driven Breakout Tests Key ResistanceParabolic SAR - newsline.com
PLSE Initiates Coverage On by Canaccord Genuity -- Price Target Set at $32 - GuruFocus
Canaccord initiates Pulse Biosciences stock with buy on ablation tech By Investing.com - Investing.com Nigeria
Canaccord Genuity Initiates Pulse Biosciences at Buy With $32 Price Target - marketscreener.com
CCORF Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $32 - Moomoo
Here's why Pulse Biosciences, Inc (PLSE) is a great momentum stock to buy - MSN
Discipline and Rules-Based Execution in PLSE Response - Stock Traders Daily
PLSE Technical Analysis & Stock Price Forecast - Intellectia AI
PLSE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pulse Biosciences (PLSE) Valuation Check After Strong Recent Share Price Momentum - Sahm
PLSE Q1 2026 Earnings: EPS Beat but No Revenue as Stock DeclinesEarnings Miss Alert - thelegaladvocate.com
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - BioSpace
Pulse Biosciences (PLSE) Holds Steady: Key Levels in FocusButterfly Setup - The Legal Advocate
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy - Yahoo Finance
Pulse Biosciences Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Pulse Biosciences (PLSE) Rises Modestly as Shares Test Key ResistanceTICK Divergence - The Legal Advocate
Assessing Pulse Biosciences (PLSE) Valuation After Recent Share Price Surge - Sahm
Pulse Biosciences Begins nPulse Study for Malignant Thyroid Tumor Treatment - Medical Product Outsourcing
Pulse Biosciences Earnings Call Highlights Clinical Momentum - TipRanks
Behavioral Patterns of PLSE and Institutional Flows - Stock Traders Daily
Pulse Biosciences, IncCommon Stock (NQ: PLSE - The Chronicle-Journal
PLSE accelerates cardiac catheter program after breakthrough AFib data - MSN
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors. - The Globe and Mail
Pulse Biosciences CEO Buys 15,000 Shares: SEC Filing Details | May 2026News and Statistics - IndexBox
Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pulse Biosciences Inc-Aktie (PLSE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
0.24%
1.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):